Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced Medidata Rave Lite, an extension of the company’s gold-standard clinical research software, Medidata Rave EDC, designed explicitly for Phase I and Phase IV studies. Regardless of company size, therapeutic focus, or pipeline, Rave Lite provides efficient electronic clinical data capture (EDC), management, and analysis solutions with a tailored pricing model.
While EDC is a fundamental building block of clinical trials, technology fragmentation across phases leads to integration challenges and delays in startup times. In particular, the lack of access to innovative technology disproportionately affects early- and late-stage studies. Having addressed these challenges in over 34,000 trials, Medidata is now offering superior options for Phase I and Phase IV studies with Rave Lite.
With Medidata Designer integration, study builders can design Phase I and Phase IV trials with speed and precision, and with the continued use of AI, potential study misconfigurations are reduced while securing data integrity. Thus, Rave Lite offers a consistent experience without sacrificing the advanced power of Rave EDC.
“Rave Lite addresses a critical need in the market for early and late-stage trials, offering a streamlined solution built on our trusted Rave EDC platform,” said Tom Doyle, chief technology officer, Medidata. “By giving our customers the ability to use one EDC ubiquitously across all phases, customers gain the flexibility to scale their studies while maintaining the high standards that have long defined Medidata’s solutions.”
Medidata will showcase Rave Lite at NEXT New York, the premier clinical trials conference hosted by the company, in New York City on November 13 and 14. The solution will be made available to customers in early 2025.
To view the original press release, please click here.
